Baroreflex Stimulation Devices

This policy covers implanted baroreflex stimulation/activation devices (eg, Barostim Neo) as adjunctive therapy for heart failure with reduced ejection fraction—specifically symptomatic NYHA Class III patients (or NYHA II with recent Class III) on guideline‑directed medical therapy with LVEF ≤35% and NT‑proBNP <1600 pg/mL. Coverage is subject to the member’s benefit plan and state rules, excludes patients indicated for CRT or with LVEF >35% or NT‑proBNP ≥1600 pg/mL, and other uses (including historical Rheos HDE hypertension indications and use after maximally tolerated guideline‑directed medical/device therapy) are considered experimental/investigational or not covered.

"Use of baroreflex stimulation devices as an alternative treatment for heart failure"

Sign up to see full coverage criteria, indications, and limitations.